MYGN vs WGS
MYGN: Myriad Genetics is a genetic testing company focused on providing actionable insights for cancer risk, reproductive health, and mental health clinical decisions. WGS: GeneDx uses AI-powered genomics to provide precise, actionable clinical genetic testing for rare and complex diseases.
Side-by-side fundamentals
| Metric | MYGN | WGS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $4.20 | $67.73 | |
| Market cap | $402M | $2.0B | |
| Net margin FY2025, SEC XBRL | -44.4% | -4.9% | WGS higher |
| Gross margin FY2025, SEC XBRL | +69.9% | +69.7% | MYGN higher |
| Operating margin FY2025, SEC XBRL | -47.0% | -3.1% | WGS higher |
| ROE FY2025, SEC XBRL | -99.4% | -6.8% | WGS higher |
| ROA FY2025, SEC XBRL | -51.8% | -4.0% | WGS higher |
| Debt / equity as of 2026-09-03 | 0.40 | 0.40 | WGS lower |
| Revenue growth (YoY) as of 2026-09-03 | -3.2% | +25.4% | WGS higher |
| Revenue CAGR (3y) SEC XBRL | +6.7% | +22.1% | WGS higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 1.10 | 1.59 | |
| 1-year return as of 2026-10-08 close | -45.0% | -44.8% | WGS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.